Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vifor Pharma

- PMLiVE

US approval for first ever cannabis-based medicine

UK company's Epidiolex tipped to be blockbuster

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

AstraZeneca AZ

PMCPA takes AZ to task over asthma drug press release

Concluded that the data in the release had not been “placed in context”

- PMLiVE

FDA clears Dova drug for liver-related low blood platelets

Drug is in the same class as Novartis’ Promacta/Revolade

AstraZeneca AZ

AZ gets US approval for Veltassa rival Lokelma

But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

- PMLiVE

AZ taps Ionis for another drug, this time in NASH

Will acquire the US pharma group’s antisense drug in a deal valued up to $330m

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

- PMLiVE

AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year

- PMLiVE

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

The studies will look at the vaccines in combination with chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links